Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033303 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT03033303: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03033303 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03033303, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also cause side effects.
Interventions
- DRUG Isotretinoin
- DRUG GM-CSF
- BIOLOGICAL Hu3F8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-01-23 |
| Est. Completion | 2025-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033303
The ClinicalTrials.gov registry entry for NCT03033303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Isotretinoin is the first listed.
NCT03033303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03033303 about?
NCT03033303 is a clinical study titled "A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma". The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also cause side effects.
What is the current status of trial NCT03033303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2017-01-23. Estimated completion is 2025-09-29.
What interventions are being tested in trial NCT03033303?
The interventions under investigation include: Isotretinoin (DRUG), GM-CSF (DRUG), Hu3F8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03033303?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.